Calcium Treatment

A treatment option for every lesion.

We offer the most advanced and complete
Modern PCI portfolio to treat all types of
coronary lesions

Clinical overview: SYNERGYTM Bioabsorbable Polymer Stent Platform

The SYNERGYTM Bioabsorbable Polymer (BP) Stent Platform has been studied in over 35,000 patients across various patient and lesion complexities.

Heal With Confidence: Leading in Complex Patients

The SYNTAX II Trial utilizing the SYNERGY BP Stent, physiological assessment, IVUS guidance, and contemporary state-of-the art PCI techniques demonstrated CABG-like outcomes in patients with three-vessel disease at 5 years.*†¹

Low rates of revascularization, peri-procedural MI, and acute ST suggests that contemporary technologies might help in reducing procedural related complications.



Consistently Low ST Rates

Kang Network Meta-Analysis

SYNERGY BP Stent ranked #1 for the lowest relative risk of def/prob ST At 1-year. §²

Kang Network Meta-Analysis

SCAAR Registry

Lowest ST rate compared to newer generation DES (n-DES) despite use in patients with statistically more Class B2/C lesions, diabetes, prior PCI, and 3VD.*,**,³

SCAAR Registry



Leading On Studying Short DAPT

Supporting well-constructed prospective Short DAPT clinical trials with over 5,000 patients to study the SYNERGY BP Stent in various complex patient populations.

EVOLVE Short DAPT Trial: Primary Endpoint Results 12 Months Post-DAPT Discontinuation

Studied the safety of discontinuing DAPT at 3-months in high bleeding risk (HBR) patients using the SYNERGY BP Stent.4

ARC definite/probable ST
vs. performance goal4

0.2% ST Rate

ARC definite/probable ST vs. performance goal chart

Adjusted death/MI with 3-month DAPT
vs. historical control4


Adjusted death/MI with 3-month DAPT vs. historical control chart

SENIOR Trial: Safety Data at 2-Years

The SYNERGY BP Stent continued to show superior results versus REBEL BMS with short BMS-like DAPT regimen at 2-years.5

All patients

All patients chart

1-month DAPT discontinuation cohort§§ 

1-month DAPT discontinuation cohort

POEM Trial: 1-year Results

At 1 year, in an all-comers HBR patient population, the SYNERGY BP Stent with 1-month DAPT beat the performance goal derived from LEADERS FREE6:

POEM Trial: 1-year results

Excellent Outcomes in Long Lesions

EVOLVE 48 Trial: Final 2-year results

Supports the safety and effectiveness of the SYNERGY XD 48 mm BP Stent for the treatment of long lesions.†††7:

  • 100 patients
  • 15 sites across US, Europe, and New Zealand
  • 100% B2/C lesions
  • 27% diabetes mellitus

Excellent Outcomes in STEMI Patients

CLEAR SYNERGY Stent Registry: Primary Endpoint Results

At 1 year, in an international, multicenter registry, the SYNERGY BP Stent demonstrated low event rates in this high-risk STEMI patient population.8

EDUCARE - Medical Education

Electrophysiology products

Education & Training with EDUCARE

Our easily accessible educational platform, EDUCARE, offers you a personalised suite to support your medical education requirements.


When we challenge the status quo,
we advance patient outcomes.

Join our Complex PCI Community

Join our Complex PCI Community

Stay up-to-date via email on the latest advances in complex PCI

Request a Sales Rep

Request a Sales Rep

Fill out a quick form and one of our sales representatives will be in touch to answer any question you have.

Download our product catalogue

Product catalogue

Download our product catalogue 2022 and stay up to date on our latest innovations.